Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women. Circulation.1997;96:2468-2482.
Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health.1998;19:55-72.
Hulley S, Grady D, Bush T.
et al. Randomized trial of estrogen plus progestin for secondary prevention
of coronary heart disease in postmenopausal women. JAMA.1998;280:605-613.
Herrington DM, Reboussin DM, Brosnihan KB.
et al. Effects of estrogen replacement on the progression of coronary-artery
atherosclerosis. N Engl J Med.2000;343:522-529.
Lenfant C. Statement from Claude Lenfant, MD, Director, National Heart, Lung,
and Blood Institute on preliminary trends in the Women's Health Initiative. WHI HRT Update. Bethesda, Md: National Heart, Lung, and Blood Institute;
April 6, 2000. Available at: http://www.nhlbi.nih.gov/whi/hrt-en.htm. Accessed January 22, 2002.
Rossouw JE. Early risk of cardiovascular events after commencing hormone replacement
therapy. Curr Opin Lipidol.2001;12:371-375.
Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med.2001;345:1243-1249.
Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and
cancer: pooled data from clinical trials. BMJ.1997;315:149-153.
Hemminki R, McPherson K. Value of drug-licensing documents in studying the effect of postmenopausal
hormone therapy on cardiovascular disease. Lancet.2000;355:566-569.
Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events
in the Nurses' Health Study: a prospective, observational study. Ann Intern Med.2001;135:1-8.
Heckbert SR, Kaplan RC, Weiss NS.
et al. Risk of recurrent coronary events in relation to use and recent initiation
of postmenopausal hormone therapy. Arch Intern Med.2001;161:1709-1713.
Alexander KP, Newby LK, Hellkamp AS.
et al. Initiation of hormone replacement therapy after acute myocardial infarction
is associated with more cardiac events during follow-up. J Am Coll Cardiol.2001;38:1-7.
Cummings SR, Eckert S, Krueger KA.
et al. The effect of raloxifene on risk of breast cancer in postmenopausal
Ettinger B, Black DM, Mitlak BH.
et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis
treated with raloxifene: results from a 3-year randomized clinical trial. JAMA.1999;282:637-645.
Cauley JA, Norton L, Lippman ME.
et al. Continued breast cancer risk reduction in postmenopausal women treated
with raloxifene. Breast Cancer Res Treat.2001;65:125-134.
Grady D, Wenger NK, Herrington D.
et al. Postmenopausal hormone therapy increases risk for venous thromboembolic
disease. Ann Intern Med.2000;132:689-696.
Fisher B, Costantino JP, Wickerham DL.
et al. Tamoxifen for prevention of breast cancer: report of the National Surgical
Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst.1998;90:1371-1388.
Walsh BW, Kuller LH, Wild RA.
et al. Effects of raloxifene on serum lipids and coagulation factors in healthy
postmenopausal women. JAMA.1998;279:1445-1451.
Walsh BW, Paul S, Wild RA.
et al. The effects of hormone replacement therapy and raloxifene on C-reactive
protein and homocysteine in healthy postmenopausal women: a randomized, controlled
trial. J Clin Endocrinol Metab.2000;85:214-218.
Saitta A, Altavilla D, Cucinotta D.
et al. Randomized, double-blind, placebo controlled study on the effects of
raloxifene and hormone replacement therapy on plasma nitric oxide concentrations,
endothelin-1 levels and endothelium-dependent vasodilation in postmenopausal
women. Arterioscler Thromb Vasc Biol.2001;21:1512-1519.
Mosca L, Barrett-Connor E, Wenger NK.
et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol.2001;88:392-395.
Rautaharju PM, Calhoun HP, Chaitman BR. NOVACODE serial ECG classification system for clinical trials and epidemiologic
studies. J Electrocardiol.1992;24(suppl):179-187.
Rautaharju PM, Park LP, Chaitman BR, Rautaharju F, Zhang ZM. The NOVACODE criteria for classification of ECG abnormalities and their
clinically significant progression and regression. J Electrocardiol.1998;31:157-187.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol
in plasma, without use of the preparative ultracentrifuge. Clin Chem.1972;18:499-502.
Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. Beta-carotene supplementation and incidence of cancer and cardiovascular
disease: the Women's Health Study. J Natl Cancer Inst.1999;91:2102-2106.
Downs JR, Clearfield M, Weis S.
et al. Primary prevention of acute coronary events with lovastatin in men
and women with average cholesterol levels. JAMA.1998;279:1615-1622.
Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy
and primary prevention of cardiovascular disease. Ann Intern Med.2000;133:933-941.
Herrington DM. The HERS trial results: paradigms lost? Ann Intern Med.1999;131:463-466.
Reis SE, Costantino JP, Wickerham DL, Tan-Chiu E, Wang J, Kavanah M. Cardiovascular Effects of Tamoxifen in Women With and Without Heart
Disease: Breast Cancer Prevention Trial. J Natl Cancer Inst.2001;93:16-21.
Cushman M, Legault C, Barrett-Connor E.
et al. Effect of postmenopausal hormones on inflammation-sensitive proteins:
the postmenopausal Estrogen/Progestin interventions (PEPI) study. Circulation.1999;100:717-722.
Cushman M, Costantino JP, Tracy RP.
et al. Tamoxifen and cardiac risk factors in healthy women: suggestion of
an anti-inflammatory effect. Arterioscler Thromb Vasc Biol.2001;21:255-261.
Zanger D, Yang BK, Ardans J.
et al. Divergent effects of hormone therapy on serum markers of inflammation
in postmenopausal women with coronary artery disease on appropriate medical
management. J Am Coll Cardiol.2000;36:1797-1802.